Cargando…

Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease

To find a new biomarker of Tay-Sachs disease and Sandhoff disease. The lyso-GM2 ganglioside (lyso-GM2) levels in the brain and plasma in Sandhoff mice were measured by means of high performance liquid chromatography and the effect of a modified hexosaminidase (Hex) B exhibiting Hex A-like activity w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kodama, Takashi, Togawa, Tadayasu, Tsukimura, Takahiro, Kawashima, Ikuo, Matsuoka, Kazuhiko, Kitakaze, Keisuke, Tsuji, Daisuke, Itoh, Kohji, Ishida, Yo-ichi, Suzuki, Minoru, Suzuki, Toshihiro, Sakuraba, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243693/ https://www.ncbi.nlm.nih.gov/pubmed/22205997 http://dx.doi.org/10.1371/journal.pone.0029074

Ejemplares similares

GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)
por: KARIMZADEH, Parvaneh, et al.
Publicado: (2014)

A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases
por: Ou, Li, et al.
Publicado: (2020)

A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)
por: Davies, Elin Haf, et al.
Publicado: (2020)

Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases
por: Lyn, Nicole, et al.
Publicado: (2020)

FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice
por: Ogawa, Yasuhiro, et al.
Publicado: (2017)

Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease
por: Demir, Seçil Akyıldız, et al.
Publicado: (2020)

Enfermedad de Tay Sachs
por: Cibrián Cruz, José Alberto
Publicado: (1996)

Identification of mutations in HEXA and HEXB in Sandhoff and Tay-Sachs diseases: a new large deletion caused by Alu elements in HEXA
por: Dastsooz, Hassan, et al.
Publicado: (2018)

Investigating Immune Responses to the scAAV9-HEXM Gene Therapy Treatment in Tay–Sachs Disease and Sandhoff Disease Mouse Models
por: Kot, Shalini, et al.
Publicado: (2021)

Therapeutic Strategies For Tay-Sachs Disease
por: Picache, Jaqueline A., et al.
Publicado: (2022)

New Approaches to Tay-Sachs Disease Therapy
por: Solovyeva, Valeriya V., et al.
Publicado: (2018)

Impaired Neural Differentiation of Induced Pluripotent Stem Cells Generated from a Mouse Model of Sandhoff Disease
por: Ogawa, Yasuhiro, et al.
Publicado: (2013)

Characterization of Inducible Models of Tay-Sachs and Related Disease
por: Sargeant, Timothy J., et al.
Publicado: (2012)

Choroidal Coloboma in a Case of Tay-Sachs Disease
por: Ahmed, Nasreen Raees, et al.
Publicado: (2014)

Tay-Sachs disease: current perspectives from Australia
por: Lew, Raelia M, et al.
Publicado: (2015)

Neuraminidase-1 contributes significantly to the degradation of neuronal B-series gangliosides but not to the bypass of the catabolic block in Tay–Sachs mouse models
por: Timur, Z.K., et al.
Publicado: (2015)

Development of a Highly Sensitive Immuno-PCR Assay for the Measurement of α-Galactosidase A Protein Levels in Serum and Plasma
por: Nakano, Sachie, et al.
Publicado: (2013)

Prenatal diagnosis of Tay-Sachs disease: our institutional experience
por: Sheth, Jayesh, et al.
Publicado: (2014)

Neurodegeneration with Progressive Dystonia: Juvenile-Onset Tay–Sachs Disease
por: Kaur, Jasmine, et al.
Publicado: (2022)

Late-Onset Tay-Sachs Disease - expanding the clinical phenotype
por: Lefter, Stela, et al.
Publicado: (2023)

Telemedicine and GM-2 gangliosidosis (Tay–Sachs) disease – A new savior on the horizon during COVID-19 pandemic
por: Grover, Rohini, et al.
Publicado: (2021)

Expanding the spectrum of HEXA mutations in Indian patients with Tay–Sachs disease
por: Sheth, Jayesh, et al.
Publicado: (2014)

Tay-Sachs' Disease: A Study of the Symptomatology and Pathology of Three Atypical Cases
por: Torrance, Herbert Watt
Publicado: (1922)

Tay-Sachs' Disease: A Study of the Symptomatology and Pathology of Three Atypical Cases
por: Torrance, Herbert Watt
Publicado: (1922)

Tay-Sachs' Disease: A Study of the Symptomatology and Pathology of Three Atypical Cases
por: Torrance, Herbert Watt
Publicado: (1922)

Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease
por: Vu, Mylinh, et al.
Publicado: (2018)

Autophagic flux is impaired in the brain tissue of Tay-Sachs disease mouse model
por: Sengul, Tugce, et al.
Publicado: (2023)

Nursing Care Plan for Patients with Tay–Sachs—A Rare Paediatric Disease
por: Cortés-Martín, Jonathan, et al.
Publicado: (2023)

Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts
por: Kitakaze, Keisuke, et al.
Publicado: (2016)

Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2021)

Serum Cytokine Profile, Beta-Hexosaminidase A Enzymatic Activity and GM(2) Ganglioside Levels in the Plasma of a Tay-Sachs Disease Patient after Cord Blood Cell Transplantation and Curcumin Administration: A Case Report
por: Shaimardanova, Alisa A., et al.
Publicado: (2021)

Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 Gangliosidosis
por: Matsuoka, Kazuhiko, et al.
Publicado: (2011)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor
por: Kanzaki, Minori, et al.
Publicado: (2020)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy
por: Kubota, Takao, et al.
Publicado: (2022)

Knowledge and attitudes toward Tay-Sachs disease among a college student population.
por: Austein, C. F., et al.
Publicado: (1981)

Comparison of enzyme and DNA analysis in a Tay-Sachs disease carrier screening program.
por: Yoo, H. W., et al.
Publicado: (1993)

Efficient and precise generation of Tay–Sachs disease model in rabbit by prime editing system
por: Qian, Yuqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ds9201ds82gbu85ao5m99a4qch